Trial site
Beijing Gobroad Boren Hospital
- 6running trials
- 5closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Conditions
- Multiple myeloma4 trials
- Acute lymphoblastic leukaemia2 trials
- Lupus (SLE)2 trials
- Amyloidosis1 trial
- Childhood cancers1 trial
- Dermatomyositis and polymyositis (myositis)1 trial
- Follicular lymphoma1 trial
- Liver and biliary tract cancer1 trial
- Multiple sclerosis1 trial
- Sjögren's disease1 trial
- Systemic sclerosis (scleroderma)1 trial
- Phase
- Early phase 14 trials
- Phase 14 trials
- Phase 22 trials
- Status
- Recruiting4 trials
- Not yet recruiting2 trials
- Terminated2 trials
- Withdrawn2 trials
- Completed1 trial
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China3 trials
- Beijing Boren Hospital2 trials
- Chongqing Precision Biotech Co., Ltd1 trial
- Circunited BioPharma (Shenzhen) Co., Ltd.1 trial
- Hutchison Medipharma Limited1 trial
- and 3 more
Running trials
Recruiting
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Recruiting
Not yet recruiting
Recruiting
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Multiple myeloma4 recruiting
- Acute lymphoblastic leukaemia1 recruiting
- Childhood cancers1 recruiting
- Lupus (SLE)1 recruiting
Closed trials
Withdrawn
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Withdrawn
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Terminated
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Terminated
Completed
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Site data: ClinicalTrials.govUpdated 12 Nov 2026